Novel Blood Filtration Technology Offers Hope for Treatment of Pancreatic Cancer

Novel Blood Filtration Technology Offers Hope for Treatment of Pancreatic Cancer

Facebook
Twitter
LinkedIn

A medical technology company focused on developing and commercializing extracorporeal blood filtration devices, ExThera Medical, has made a groundbreaking breakthrough in the field of advanced pancreatic cancer treatment.

Researchers had successfully deployed Seraph® 100 blood filtration media, a novel cancer treatment technology designed to remove Circulating Tumor Cells (CTCs) from pancreatic cancer patients’ bloodstream, according to ExThera Medical’s announcement on Thursday, July 18.

This can potentially prevent the spread of cancer cells from the tissues where they are initially formed to other parts of the body.

The published research results form a crucial foundation for the company’s revolutionary circulating tumor cell-reducing device, the ONCObind™ Procedure Hemoperfusion Filter (ONCObind™).

By removing circulating tumor cells from cancer patient’s blood, this innovative medical device can help improve treatment outcomes and improve longevity.

ONCObind™ leverages the novel Seraph® 100 technology to filter tumor cells from circulating blood, preventing their spread to other healthy tissues. According to the researchers, the hemoperfusion media successfully reduced tumor cells in blood samples taken from patients diagnosed with pancreatic cancer.

Why Blood Filtration Technology Could be a Game-changer in Oncology

Since most cancers become deadly when spread from the first point of occurrence to other parts of the body, CTCs, which travel through the patient’s bloodstream, play a vital role in disrupting the spread of metastatic cancer, resulting in improved outcomes.

According to the research paper’s authors, purifying blood using Seraph® 100 media alone or combined with other existing therapies could be considered a pioneering technology in treating PDAC.

Dr. Peter Kuhn, PhD, the study’s lead researcher, and other co-authors of the report affirmed that the novel blood filtration device presents an immense opportunity to improve the care of pancreatic cancer patients and has potential application in treating other types of cancer.